PT Kalbe Farma Tbk (PTKFY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDR tn | 23 | 26 | 29 | 30 | 33 | 35 | 38 | 39 |
| Operating profit | IDR tn | 5 | 5 | ||||||
| Net profit | IDR tn | 3 | 3 | 3 | 3 | 3 | 4 | 4 | - |
| EPS reported | IDR | 16,176 | 16,084 | ||||||
| Operating cashflow per share | IDR | 14,435 | 14,280 | ||||||
| Capex per share | IDR | 3,574 | 3,465 | ||||||
| FCF per share | IDR | 10,861 | 10,815 | ||||||
| Free cash flow | IDR tn | 2 | 2 | ||||||
| Net debt | IDR tn | -4 | -4 | ||||||
| Book value equity | IDR tn | 23 | 24 | ||||||
| Book value per share | IDR | 102,889 | 107,973 | ||||||
| Number of shares | m | 226.58 | 226.24 | ||||||
| DPS (TTM paid) | IDR | 4,024 | 4,024 |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 13.91 | 8.46 | ||||||
| P/B LTM | x | 2.19 | 2.09 | ||||||
| P/S LTM | x | 1.45 | 1.35 | ||||||
| P/FCF LTM | x | 20.78 | 20.46 | ||||||
| EV/EBITDA LTM | x | 9.09 | 8.74 | ||||||
| EV/Sales LTM | x | 1.33 | 0.79 | ||||||
| Earnings Yield LTM | % | +7.19% | +11.82% | ||||||
| FCF Yield | % | +4.81% | +4.89% | ||||||
| Quality | |||||||||
| ROE | % | +15.72% | +15.56% | ||||||
| ROIC | % | +13.97% | +13.15% | ||||||
| Operating margin | % | +12.87% | +12.30% | ||||||
| Gross margin | % | +39.79% | +38.67% | ||||||
| FCF/Sales | % | +6.97% | +6.77% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +15.28% | +14.62% | ||||||
| Sales Growth YoY | % | +8.27% | +16.19% | ||||||
| Net Income Growth YoY | % | +13.10% | +11.95% | ||||||
| FCF Growth | % | -30.38% | -29.30% | ||||||
| Operating Profit Growth | % | +11.74% | +13.08% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +3.20% | +2.76% | ||||||
| Dividend Growth | % | -44.43% | -44.43% | ||||||
| Payout Ratio | % | +44.63% | +45.01% | ||||||
| FCF/Debt | x | 8.28 | 3.01 | ||||||
| Net Debt/EBITDA | x | -0.78 | -0.77 | ||||||
| EBIT/Net interest | x | 128.95 | 146.03 | ||||||
| Net debt/market cap | % | +0.50% | +0.78% | ||||||
| Net debt/Equity | x | -0.18 | -0.17 | ||||||
| Gross debt/equity | x | 0.01 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free